The company will analyze up to 60,000 substance samples to evaluate the potential toxicity effects on the human body by using its cost-effective proprietary technology.
Commenting on the contract BioSeek general manager Dr. Ellen Berg remarked that the combined efforts of the company and the agency are tuned towards ascertaining the effects of various environmental compounds on the human body.
EPA awarded the contract under the agency’s ToxCast program that seeks to verify the toxicity signatures of substances.
"Our partnership with EPA under the ToxCast program has been a highly productive relationship with well over 1,000 samples, including chemicals, failed pharmaceutical compounds and nanomaterials analyzed to date," said Dr. Berg
